Anterior Mitral Valve Leaflet Augmentation
The Only Transcatheter Solution to Functional Mitral Regurgitation
About LeaFix
LeaFix developed the only Transcatheter Functional Mitral valve Regurgitation repair solution, performed by an augmentation of the anterior leaflet. The system is composed of an implant and a delivery system, used for implantation of an implant into the anterior leaflet while expanding the implant within the leaflet, hence enlarging the leaflet area and creating coaptation of the leaflets.
Functional Mitral Regurgitation
Secondary mitral regurgitation (also known as functional MR) is MR caused by left ventricular (LV) disease (dilation, abnormal shape and/or dysfunction) and/or dilation of the left atrium and mitral annulus, generally with structurally normal or minimally thickened mitral valve leaflets and chordae.
The Market
Trans-catheter mitral valve repair was valued at $1.6 billion in 2023 and is expected to reach $2.45 billion by 2030 exhibiting a CAGR of 6.1%.